Frontier Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Frontier Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-221,369	Closed	-$3.54M	–	349
2016 Q1	$3.54M	Sell	221,369 -159,065	-42%	-$3.02M	0.03%	283
2015 Q4	$10.9M	Buy	380,434 +111,213	+41%	+$3.08M	0.09%	242
2015 Q3	$7.66M	Sell	269,221 -13,368	-5%	-$492K	0.06%	264
2015 Q2	$10.2M	Sell	282,589 -427,001	-60%	-$13.3M	0.07%	263
2015 Q1	$20.6M	Buy	709,590 +238,676	+51%	+$6.31M	0.15%	211
2014 Q4	$9.93M	Buy	+470,914	New	+$9.31M	0.07%	263

Other funds holding INSY

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Frontier Capital Management's INSY Position: Q2 2016 in Review

Frontier Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 221,369 shares — an estimated $3.54M sold.

Frontier Capital Management first reported a position in INSY in Q4 2014 and held it in 6 quarters. The position peaked at $20.6M in Q1 2015. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

Frontier Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Frontier Capital Management sold 221,369 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $3.54M.
Frontier Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
Frontier Capital Management's Insys Therapeutics, Inc. position peaked at $20.6M in Q1 2015.
124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Frontier Capital Management's 13F filing for Q2 2016, filed 2 Aug 2016.